News
AstraZeneca's human monoclonal antibody Imfinzi (durvalumab), when combined ... The multi-centre, open-label, global study is assessing the combo in 1,018 BCG-naïve NMIBC subjects after ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback